[
    [
        {
            "time": "2021-11",
            "original_text": "【兴证医药】医药持仓比例历史低位，自下而上布局2022年-2021年11月投资月报",
            "features": {
                "keywords": [
                    "医药",
                    "持仓比例",
                    "历史低位",
                    "布局"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【兴证医药】医药持仓比例历史低位，自下而上布局2022年-2021年11月投资月报",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-11",
            "original_text": "高瓴，正在抛弃医药股？",
            "features": {
                "keywords": [
                    "高瓴",
                    "医药股",
                    "抛弃"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "高瓴，正在抛弃医药股？",
                "Correlation": 7,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11",
            "original_text": "如果现在就是医药极度悲观的底部，未来该如何布局？",
            "features": {
                "keywords": [
                    "医药",
                    "悲观",
                    "底部",
                    "布局"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "如果现在就是医药极度悲观的底部，未来该如何布局？",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-Q3",
            "original_text": "高瓴资本3季度只减仓不加仓：安全边际、成长性重定位",
            "features": {
                "keywords": [
                    "高瓴资本",
                    "减仓",
                    "安全边际",
                    "成长性",
                    "重定位"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "高瓴资本3季度只减仓不加仓：安全边际、成长性重定位",
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-Q3",
            "original_text": "泰格医药：公司目前经营情况正常",
            "features": {
                "keywords": [
                    "泰格医药",
                    "经营情况",
                    "正常"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "泰格医药：公司目前经营情况正常",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-Q3",
            "original_text": "【权益变动】泰格医药(03347.HK)获Sands Capital Management, LLC增持62.11万股",
            "features": {
                "keywords": [
                    "泰格医药",
                    "Sands Capital Management",
                    "增持"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【权益变动】泰格医药(03347.HK)获Sands Capital Management, LLC增持62.11万股",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-Q3",
            "original_text": "【权益变动】泰格医药(03347.HK)获Aggregate of abrdn plc affiliated investment增持40.13万股",
            "features": {
                "keywords": [
                    "泰格医药",
                    "Aggregate of abrdn plc",
                    "增持"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【权益变动】泰格医药(03347.HK)获Aggregate of abrdn plc affiliated investment增持40.13万股",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-Q3",
            "original_text": "高瓴资本三季度只减仓不加仓，安全边际与成长性需重新定位",
            "features": {
                "keywords": [
                    "高瓴资本",
                    "减仓",
                    "安全边际",
                    "成长性",
                    "重新定位"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "高瓴资本三季度只减仓不加仓，安全边际与成长性需重新定位",
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]